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Abstract
Various inhibitors have been developed for neuraminidase but resistance against these drugs in many viral strains makes it
an advantageous and interesting task to discover compounds which can be more promising in preventing viral infection through
neuraminidase. Virtual screening methods have been proved as an efficient in silico approach for drug discovery processes. In
the present study, we used ligand based virtual screening process for identifying potent inhibitors against viral neuraminidase
enzyme. The approach utilized in this study has been successful in identifying 15 compounds which may be potential inhibitors
of neuraminidase. These compounds were screened via three screening platforms (MVD, PyRx, and FRED) by setting oseltamivir
as reference compound, which is an FDA approved drug against influenza virus. These compounds were then filtered by their in
silico ADME/T (Absorption, Distribution, Metabolism, Excretion, and Toxicity) values and only 12 of them were found to have
comparatively better results. The results of the present study are reported herein so that researchers, who are having required
laboratory facilities for synthesizing drugs, can utilize findings of this study for developing new drugs against influenza with better
efficacy.
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1.  Introduction
Some of the reported worst epidemics in the history of
humans have been caused by influenza viruses. Influenza
viruses contain two major glycoproteins attached on
their surface: haemagglutinin (HA) and neuraminidase
(NA). Haemagglutinin helps virus in the attachment and
penetration of host cells via sialic acid binding sites
[1,2] and neuraminidase enzymatically cleaves bond-. This is an open access article under the CC BY-NC-ND license
ing between haemagglutinin and sialic acid from cell
surface glycoconjugates and thus facilitates the release
of progeny virions from infected cells, spreads the new
virus particles, and prevents the aggregation of progeny
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accesses via a relatively slow conformational change.
It should therefore be possible to design new inhibitors
for group-1 neuraminidases that are selective for theV. Mishra et al. / Journal of Taiba
irions [3,4]. According to different antigenic proper-
ies of haemagglutinin and neuraminidase molecules,
nfluenza type A viruses can be classified into 16 sub-
ypes by haemagglutinin (H1–H16) and 9 subtypes by
euraminidase (N1–N9) [5]. Numerous combinations of
aemagglutinin and neuraminidase subtypes have been
ound in influenza type A viruses on avian species, i.e.
ird flu. Among them, H5N1 has received extensive
ttention in recent years since it has caused a consid-
rable number of human lives worldwide [6].
In theory, both haemagglutinin and neuraminidase
an be considered as therapeutic targets for preven-
ing the replication and spread of influenza viruses in
ost cells. Although the crystal structure of haemag-
lutinin was already resolved in early 1980s [7], no
ightly binding compounds have been discovered for
t. As for neuraminidase, many inhibitors with high
otencies have been developed. For example, zanamivir
nd oseltamivir (Tamiflu) are two successful drugs cur-
ently in use [8,9]. Nevertheless, resistance against these
rugs has subsequently been developed by influenza
iruses, still making the development of new classes of
euraminidase inhibitors a significant and urgent task
10,11]. Neuraminidase was chosen as a suitable drug
arget because NA plays a major role in influenza virus
ropagation, and the amino acid residues of the active site
nteracting directly with the substrate or surrounding the
entral active site of the enzyme are strictly conserved
12].
Virtual screening (VS) is considered as computa-
ional approach of high throughput screening (HTS)
nd refers to the in silico evaluation of properties of
ifferent molecular scaffolds including binding affinity,
nteraction energy, etc. Different applications of machine
earning to virtual screening have been presented in the
iterature including both ligand-based similarity search-
ng and structure-based docking. The main purpose of
uch applications is to prioritize databases of molecules
s active against a particular protein target. Some case
tudies presented in the same perspective suggest that
S has already played a significant role in the discovery
f some compounds that are now in the clinical trial or
ven in the market [13–18].
. Materials  and  methods
.1.  Selection  and  preparation  of  target/receptor
rotein  for  dockingTarget neuraminidase protein (PDB ID: 2HU0) was
btained from the Protein Data Bank (PDB) which is a
epository for the 3-D structural data of large biologi-Fig. 1. Active site of NA predicted by MVD (active site residues:
Arg118, Asp151, Arg152, Arg156, Trp178, Ser179, Ile222, Arg224,
Ser246, Glu276, Glu277, Arg292, Asn294, Arg371, Tyr347, Tyr406).
cal molecules [19]. This protein was selected as target
because the observation of the open conformation for the
150-loop in the group-1 structures suggests that, for these
enzymes, this conformation of the loop is intrinsically
lower in energy than the closed conformation. Group-1
neuraminidases (N1 and N8) initially bind to oseltamivir
in this open conformation but eventually adopt the closed
conformation. It thus seems that oseltamivir binding
to group-1 neuraminidases favors the higher energy or
closed conformation of the 150-loop that it probablyFig. 2. Superimposed image of highest ranking docked conformer
(blue) and co-crystallized neuraminidase with oseltamivir (2HU0)
(purple).
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Fig. 3. (A–D) The docked poses of oseltamivir, zanamivir, peramivir, and laninamivir respectively within the binding pocket of neuraminidase
 steric inshowing their different interactions (hydrogen bonds, electrostatic and
open 150-loop conformation and would thereby have
the potential to bind more strongly than oseltamivir or
zanamivir [20].
2.2.  Cavity  detection  and  selection
Possible active site(s)/cavities for the target protein
(2HU0) of interest were determined with the help of
Molegro Virtual Docker (MVD) [21]. A number of cav-
ities were detected for the same protein but only one
cavity was selected as active site on the basis of prior
information about the active site residues, available in
literatures. This cavity was utilized in further docking
studies.
2.3. Ligand  screening  from  ZINC  database  (version
12)
Ligands were screened from ZINC database on the
basis of structural similarity with known neuraminidase
inhibitors (oseltamivir, zanamivir, peramivir and lani-
namivir) [22–25]. 70% structural similarity was used
as cut off for database screening. On the basis of
oseltamivir, zanamivir, peramivir and laninamivir 30, 57,
3, and 58 analogs were found respectively. Out of 58
analogs of laninamivir 57 were common for both lan-teractions are shown in blue, green and red dotted lines respectively).
inamivir and zanamivir and one was different (ZINC
ID 71974042), common analogs were considered only
once.
3. Results  and  discussion
3.1.  Active  site  analysis
The active sites of all influenza neuraminidases con-
tain three arginine residues – Arg118, Arg292 and
Arg371 – that bind the carboxylate of the substrate sialic
acid, one arginine residue, Arg152, interacts with the
acetamido substituent of the substrate, and one glutamine
residue, Glu276, forms hydrogen bonds with the 8- and
9-hydroxyl groups of the substrate [20]. Binding pocket
of NA, as predicted by MVD and supported by various
literatures, is given in Fig. 1 along with their amino acid
residues.
3.2. Selection,  validation  and  evaluation  of  docking
protocolIn molecular docking, validation of docking proto-
col is a necessary step in order to ensure that ligands
bind within the binding pocket in the correct con-
formation which is done by validating the size and
V. Mishra et al. / Journal of Taibah University for Science 9 (2015) 20–26 23
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known inhibitorsig. 4. (A–L) The docked structures of virtually screened compounds 
heir overall interactions.
enter of the coordinates of the grid box across the
inding pocket [26]. In this work, docking protocol
as validated by redocking co-crystallized structure of
euraminidase in complex with oseltamivir (PDB ID:
HU0). During redocking various algorithms were used
hich are available in MVD and it was observed that
ost suited algorithm was MolDock SE (Simplex Evo-
ution) search algorithm. All binding conformations of
edocked oseltamivir within the binding pocket of NA
roduced by MolDock SE algorithm were similar to
inding mode of the co-crystallized ligand, and the rootME/T filtration within the binding pocket of neuraminidase showing
mean square deviation (RMSD) for these conformations
were below 2 A˚ [27]. The RMSD of best pose was 1.75 A˚,
interaction energy (between target protein and ligand)
was −100.69 kcal/mol and hydrogen bond energy was
−11.69 kcal/mol, Fig. 2.
3.3.  Analysis  of  interactions  and  binding  poses  ofAll the four known inhibitors were re-docked
within the binding pocket of neuraminidase and their
24
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Table 1
Virtually screened compounds on the basis of various scoring functions.
Ligand
name
ZINC ID E-Inter (protein–ligand
interaction energy in
kJ/mol)
Energy (kJ/mol) or
MolDock Score
H bond energy
(kJ/mol)
LE1 LE3 MW Rerank Score
(a.u.)
Steric
interaction
(kJ/mol)
VdW (LJ12-6)
(kJ/mol)
Similarity
(w.r.t.
oseltamivir)
No of
H-bonds
Binding
affinity (PyRx)
(kcal/mol)
Pose score
(FRED)
C1 ZINC03929508 −125.705 −104.972 −11.1686 −4.77146 −3.4799 313.412 −76.5578 −106.988 −17.9726 32.0808 7 −6.5 −26.88
RC2 ZINC03918138 −140.869 −120.679 −20.0388 −5.24689 −3.84836 332.31 −88.5123 −121.083 −37.8168 18.6352 10 −7.2 −34.30
RC3 ZINC03981610 −126.69 −125.005 −15.4094 −5.43498 −3.76797 328.407 −86.6634 −96.7167 −15.7241 21.2183 9 −6.7 −34.26
RC4 ZINC03985629 −127.088 −103.138 −25.5124 −4.2974 −2.96609 346.336 −71.1861 −84.5985 5.40812 33.1139 13 −7.2 −30.97
VS1 ZINC22012077 −132.346 −127.995 −25.9599 −5.33314 −4.25503 338.402 −102.121 −106.386 −35.0829 20.6627 14 −6.7 −33.00
VS2 ZINC22047629 −146.301 −121.596 −8.52048 −3.68472 −2.24388 473.428 −74.0479 −137.781 −1.00072 23.528 4 −7.1 28.79
VS3 ZINC22047634 −151.225 −136.077 −21.2061 −4.12354 −2.93814 473.428 −96.9585 −130.019 −40.8673 27.4237 11 −7.4 −28.84
VS4 ZINC26284236 −130.935 −121.342 −17.9446 −5.27575 −3.54091 332.31 −81.441 −108.726 3.32461 18.7158 11 −7.0 −34.42
VS5 ZINC29559740 −125.638 −114.955 −22.3746 −4.7898 −4.18879 346.336 −100.531 −90.4354 −30.5518 22.693 9 −7.2 −30.00
VS6 ZINC33676598 −152.037 −151.737 −22.3478 −4.59809 −2.77607 473.428 −91.6103 −129.689 −1.22205 43.5508 12 −6.6 −27.55
VS7 ZINC33676599 −155.43 −142.93 −18.8045 −4.3312 −2.97458 473.428 −98.1612 −136.626 −45.4967 35.0065 9 −7.1 −30.14
VS8 ZINC33676602 −148.948 −136.9 −14.2166 −4.14848 −3.02718 473.428 −99.8971 −134.731 −44.0123 27.7475 10 −7.4 −27.38
VS9 ZINC35645304 −140.523 −123.43 −19.629 −3.7403 −1.72349 473.428 −56.8752 −120.894 38.7106 18.3914 11 −6.8 −28.34
VS10 ZINC37033736 −133.937 −116.808 −29.2808 −5.07863 −3.58839 332.31 −82.533 −90.8218 6.01711 21.5714 16 −6.9 −32.62
VS11 ZINC40641191 −134.246 −123.034 −29.5452 −5.34932 −3.01232 332.31 −69.2834 −92.6921 34.3449 20.395 14 −6.8 −33.16
VS12 ZINC44136660 −138.916 −132.874 −24.0434 −4.42914 −3.38108 430.406 −101.432 −114.873 −42.5319 22.5911 11 −7.3 −33.06
VS13 ZINC65739846 −127.233 −114.735 −7.59441 −5.46358 −4.61402 297.373 −96.8943 −109.426 −31.7841 25.2443 5 −6.6 −33.19
VS14 ZINC65739850 −127.434 −115.528 −15.1424 −5.50135 −3.71704 297.373 −78.0578 −102.989 −4.83545 21.8996 9 −6.5 −35.68
VS15 ZINC06692561 −127.657 −101.861 −15.4738 −5.09303 −4.82693 290.247 −96.5387 −108.535 −34.8038 24.9761 7 −6.7 −32.36
Table 2
Comparative chart for ADME/T values of screened compound along with reference compound oseltamivir (RC1).
Ligand name (ZINC ID) Properties of ligand ADME/T values
MW HA HD LP PSA A D M E T
RC1 (ZINC03929508) 313.418 6 4 0.85 93.85 1 3 5 3 0
VS2 (ZINC22047629) 473.431 13 1 0.12 171.39 1 4 5 4 0
VS3 (ZINC22047634) 473.431 13 1 0.12 171.39 1 4 5 4 0
VS4 (ZINC26284236) 226.277 4 0 1.46 60.44 1 4 6 3 0
VS5 (ZINC29559740) 346.34 11 8 −3.24 170.86 1 4 6 3 0
VS6 (ZINC33676598) 473.431 13 1 0.21 171.39 1 4 5 4 0
VS7 (ZINC33676599) 473.431 13 1 0.21 171.39 1 4 5 4 0
VS8 (ZINC33676602) 473.431 13 1 0.21 171.39 1 4 5 4 0
VS9 (ZINC35645304) 473.431 13 1 0.21 171.39 1 4 5 4 0
VS10 (ZINC37033736) 332.313 11 9 −3.67 181.86 1 4 6 3 0
VS11 (ZINC40641191) 332.313 11 9 −3.51 193.48 1 4 6 3 0
VS12 (ZINC44136660) 430.41 12 3 −0.99 158.682 1 4 5 4 0
VS15 (ZINC06692561) 290.248 9 5 −3.01 160.98 1 4 5 2 0
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nteractions were analyzed with the help of MVD,
ig. 3A–D.
.4. Docking  study  for  screening  of  unknown
nhibitors
All the 91 different analogs of known inhibitors that
ere screened from ZINC database were docked within
he binding pocket of neuraminidase with the help of
olegro Virtual Docker, PyRx (Autodock Vina) and
RED [21,28–30]. Only those compounds were selected
fter screening that showed positive result from all the
hree docking platforms and were having better bind-
ng affinity, docking score, similarity with the known
nhibitors and other scoring functions (Table 1). Poses
or the unknown inhibitors were evaluated on the basis
f various factors such as by comparing their hydro-
en bonding interaction patterns and overall interaction
verlay with the known inhibitors, etc.
.5.  ADME/T  studies
APOD (abbreviated profile of drugs) calculates
DME/T values of a compound with respect to a ref-
rence compound (RC) on the basis of their molecular
roperties such as molecular weight (MW), hydro-
en bond donor (HD), hydrogen bond acceptor (HA),
ipophilicity (LP), and polar solvent accessibility (PSA)
nd creates a comparative chart of ADME/T values for
oth the compounds. ADME/T (Absorption, Distribu-
ion, Metabolism, Excretion, and Toxicity) values were
alculated with the help of APOD for all the 15 com-
ounds that were screened after ligand based virtual
creening and it was found that only 12 of them (Table 2)
howed better results than oseltamivir (RC1) in terms
f Distribution, Metabolism and Excretion, whereas
bsorption and Toxicity values of these compounds
ere found same as of oseltamivir (RC1). Interaction
aps of the compounds that showed better results after
DME/T filtering are shown in Fig. 4A–L.
. Conclusions
Virtual screening methods are widely used for reduc-
ng cost and time of drug discovery process. In this
tudy, we used only oseltamivir standards (various
cores and binding energy) as a cutoff for screening
f new and potential inhibitors because oseltamivir is
n FDA approved drug and was discovered via struc-
ure based approach [20,9], and when we set oseltamivir
s a standard for screening other known inhibitors
zanamivir, peramivir, and laninamivir) the possibilityrsity for Science 9 (2015) 20–26 25
of success of this approach in identification of true
positive inhibitors was 100%, because it was able to
screen all the three other known inhibitors as true
positive, whereas on using other inhibitors as standard
the rate of success had decreased. This approach was
successful in identifying 15 compounds which may
behave as potential inhibitors. These compounds were
screened via three screening platforms (MVD, PyRx, and
FRED). The docked poses of these compounds resem-
ble similar orientation as observed with neuraminidase
ligand (oseltamivir). These ligands were docked deeply
inside the binding pocket of NA forming interactions
with ARG118, ASP151, ARG152, ARG156, TRP178,
SER179, ILE222, ARG224, SER246, GLU276, and
GLU277 [20]. These compounds were further filtered
by their in silico ADME/T (Absorption, Distribution,
Metabolism, Excretion, and Toxicity) values and only
12 of them were found as comparatively better than or
as potential as oseltamivir. Therefore, this study shows
the importance of this hypothesis in screening of small
molecule libraries and their use to intensify drug discov-
ery process before synthesis.
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